Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 17Endocrine 10CNS 6Gastrointestinal 5Thoracic 4Gynecologic 4Genitourinary 4Dermatologic 4NET 3Breast 3Sarcoma 2Other hematologic neoplasm 2Lymphoid 2Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Myeloid, Acute 13Hematologic Neoplasms 10Burkitt Lymphoma 10Lymphoma, Large B-Cell, Diffuse 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Follicular 8Myelodysplastic Syndromes 7Lymphoma 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Biphenotypic, Acute 5Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Waldenstrom Macroglobulinemia 3Mycosis Fungoides 3Melanoma 3Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Chronic 3Immunoblastic Lymphadenopathy 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Sezary Syndrome 2Prostatic Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1cc-486 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Surveys and Questionnaires 1Sunitinib 1Specimen Handling 1Quality of Life 1Psychology, Positive 1Patient Reported Outcome Measures 1Palliative Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Magnetic Resonance Spectroscopy × Other hematologic neoplasm × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04459273 2026-02-05

FAPI PET RDRC

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
26 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasm

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Unknown Primary, Skin Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡